Cardiotoxicity of cancer therapy

Cancer Investigation

Volumn 17, Issue 6, 1999, Pages 408-422

  Tolba, Khaled A ^a,c   Deliargyris, Efthymios N ^b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMSACRINE; ANTHRACYCLINE ANTIBIOTIC AGENT; BIOLOGICAL RESPONSE MODIFIER; CARDIOPROTECTIVE AGENT; CREMOPHOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; INDIUM 111; INTERFERON; INTERLEUKIN 2; MITOXANTRONE; PACLITAXEL; PRENYLAMINE; RAZOXANE; TANTALUM 178; UBIDECARENONE; UNCLASSIFIED DRUG;

BONE MARROW TRANSPLANTATION; BRADYCARDIA; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DRUG MECHANISM; ECHOCARDIOGRAPHY; HEART BLOCK; HEART PROTECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IONIZING RADIATION; LEUKEMIA; META ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0032795759     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909909021433     Document Type: Review

References (165)

1. Zujewski J, Nelson A, Abrams J: Much ado about not. . . enough data: High-dose chemotherapy with autologous stem cell rescue for breast cancer. J Natl Cancer Inst 90:200-209, 1998.
2. Rowlings PA, Horowitz MM, Armitage JO, et al: Report for the International Bone Marrow Transplant Registry and the North American Autologous Bone Marrow Transplant Registry. In: Clinical Transplants in 1993, edited by PI Teraski, JM Cecka, Los Angeles, CA, UCLA Tissue Typing Laboratory, 1994, pp. 101-108.
3. Gratwohl A, Hermans J, Baldomero H: Blood and marrow transplantation activity in Europe 1995. Bone Marrow Transplant 19: 407-419, 1997.
4. Geller RB: Use of cytokines in the treatment of acute myeloid leukemia: a critical review. J Clin Oncol 14:1371-1382, 1996.
5. Bleyer WA: The impact of childhood cancer on the United States and the world. CA Cancer J Clin 40:355-367, 1990.
6. Lefrak EA, Pitha J, Rosenheim S, et al: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32:302-314, 1973.
7. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 91: 710-717, 1979.
8. Stewart CF, Ratain M: Topoisomerase interactive agents. In: Cancer: Principles and Practice of Oncology, 5th edition, edited by VT DeVita, S Hellman, SA Rosenberg, Philadelphia-New York, Lippincott-Raven, 1997, pp. 452-467.
9. Allen A: The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 19:529-542, 1992.
10. Nielsen D, Jensen JB, Dombernowsky P, et al: Epirubicin cardiotoxicity: A study of 135 patients with advanced breast cancer. J Clin Oncol 8:1806-1810, 1990.
11. Dardir MD, Ferrans VJ, Mikhael YS, et al: Cardiac morphologic and functional changes induced by epirubicin chemotherapy. J Clin Oncol 7:947-958, 1989.
12. Launchbury AP, Habboubi N: Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 19:197-228, 1993.
13. Amantea MA: Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Clin Pharmacol Ther 61:301-311, 1997.
14. Gottlieb JJ: Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin. Lancet 350:1363-1364, 1997.
15. Gabizon A, Martin F: Polyethylene glycol-coated (pegylated) liposomal doxorubicin: rationale for use in solid tumors. Drugs 54(Suppl4):15-21, 1997.
16. Legha SS, Benjamin RS, Mackay B, et al: Reduction of cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96:133-139, 1982.
17. Workman P: Infusional anthracyclines: is slower better? If so why? Ann Oncol 3:591-594, 1992.
18. Working PK, Dayan AD: Pharmacological-toxocological expert report: Caelyx (Stealth liposomal doxorubicin HCL). Hum Exp Toxicol 15:752-785, 1996.
19. Forssen EA, Tokes ZA: Use of anionic liposomes for reduction of chronic doxorubicin-induced cardiotoxicity. Proc Natl Acad Sci USA 78:1873-1877, 1981.
20. Gabizon A, Meshorer A, Barenholtz Y: Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J Natl Cancer Inst 77:459-469, 1986.
21. Goebel FD, Goldstein D, Goos M, et al: Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Br J Cancer 73:989-994, 1996.
22. Harrison M, Tomlinson D, Stewart S, et al: Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 13:914-920, 1995.
23. Northfelt DW, Dezube BJ, Thommes JA, et al: Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 15:653-659, 1997.
24. Stewart S, Jablonowski H, Goebel FD, et al: Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 16:683-691, 1998.
25. Ranson MR, Carmichael J, O'Byrne K, et al: Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 15: 3185-3191, 1997.
26. Berry G, Billingham M, Alderman E, et al: Reduced cardiotoxicity of Doxil (pegylated liposomal doxorubicin) in AIDS Kaposi's sarcoma patients compared to a matched control group of cancer patients given doxorubicin [abstract no. 843]. Proc Am Soc Clin Oncol 15:303, 1996.
27. Gianni L, Myers C: The role of free radical formation in the cardiotoxicity of anthracycline. In: Cancer Treatment and the Heart, edited by F Muggia, M Green, J Speyer, Baltimore, The Johns Hopkins University Press, 1992, pp.9-46.
28. Doroshow J: Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 43:460-472, 1983.
29. Fujita N, Hiroe M, Ohta Y, et al: Chronic effects of metoprolol on myocardial β-adrenergic receptors in doxorubicin-induced cardiac damage in rats. J Cardiovasc Pharmacol 17:656-661, 1991.
30. Shi F, MacEwen EG, Kurzman ID: In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation. Cancer Res 53:3986-3991, 1993.
31. Torre-Amione G, Kapadia S, Lee J, et al: Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 92:1487-93, 1995.
32. Hegewisch S, Weh HJ, Hossfeld DK: TNF-induced cardiomyopathy [letter]. Lancet 335:294-295, 1990.
33. Bristow MR, Thompson PD, Martin RP, et al: Early anthracycline cardiotoxicity. Am J Med 65:823-832, 1978.
34. Steinberg JS, Cohen AJ, Wasserman AG, et al: Acute arrhythmogenicity of doxorubicin administration. Cancer 60:1213-1218, 1987.
35. Dindogru A, Barcos M, Henderson ES, et al: Electrocardiographic changes following adriamycin treatment. Med Pediatr Oncol 5:65-71, 1978.
36. Wortman JE, Lucas VS, Schuster E, et al: Sudden death during doxorubicin administration. Cancer 44:1588-1591, 1979.
37. Goorin AM, Borow KM, Goldman A, et al: Congestive heart failure due to adriamycin cardiotoxicity: its natural history in children. Cancer 47:2810-2816, 1981.
38. Steinhertz LJ, Steinhertz PG, Tan CTC, et al: Cardiotoxicity 4-20 years after completing anthracycline therapy. JAMA 266: 1672-1677, 1991.
39. Torti FM, Bristow MR, Howes AE, et al: Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med 99:745-749, 1983.
40. Krischer JP, Epstein S, Cuthbertson DD, et al: Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the pediatric oncology group experience. J Clin Oncol 15:1544-1552, 1997.
41. Lipshultz SE, Lipsitz SR, Mone SM, et al: Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 26:1738-1743, 1995.
42. Lipshultz SE, Colan SD, Gelber RD, et al: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324:808-815, 1991.
43. Ito H, Miller SC, Billingham ME, et al: Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci USA 87:4275-4279, 1990.
44. Rodvold KA, Rushing DA, Tewksbury DA: Doxorubicin clearance in the obese. J Clin Oncol 6:1321-1327, 1988.
45. Piazza E, Natale N, Trabatonni A, et al: Plasma and tissue distribution of adriamycin in patients with pelvic cancer. Tumori 67: 533-537, 1981.
46. Tanner JM, Whitehouse RH: Revised standards for triceps and subscapular skin folds in British children. Arch Dis Child 50: 142-145, 1975.
47. Silber JH, Jakacki RI, Larsen RL, et al: Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol 21: 477-479, 1993.
48. Bradley G, Georges E, Ling V: Sex-dependent and independent expression of the P-glycoprotein isoforms in Chinese hamster. J Cell Physiol 145:398-408, 1990.
49. Dobbs NA, Twelves CJ, Gillies H, et al: Gender effects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 36:473-476, 1995.
50. Weiss AJ, Metter GE, Fletcher WS, et al: Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 60:813-822, 1976.
51. Torti FM, Bristow MR, Howes AE, et al: Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule: assessment by endomyocardial biopsy. Ann Intern Med 99:745-749, 1983.
52. Legha SS, Benjamin RS, Mackay B, et al: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96:133-139, 1982.
53. Bejamin RS: The schedule dependency of the cardiotoxicity of adriamycin: its relevance to pharmacokinetic parameters. In: Cancer Treatment and the Heart, edited by FM Muggia, MD Green, JL Speyer, Baltimore, Johns Hopkins University Press, 1992, pp. 278-285.
54. Legha SS, Wang YM, Mackay B, et al: Clinical and pharmacologic investigation of the effects of alpha-tocopherol on Adriamycin cardiotoxicity. Ann NY Acad Sc: 393:411-418, 1982.
55. Myers C, Bonow R, Palmeri S, et al: A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetyl cysteine. Semin Oncol 10(Suppl 1):53-55, 1983.
56. Okuma K, Furuta I, Ota K: Protective effect of coenzyme Q10 in cardiotoxicity induced by adriamycin. Gan To Kagaku Ryoho 11:502-508, 1984.
57. Milei J, Marantz A, Ale J, et al: Prevention of adriamycin-induced cardiotoxicity by prenylamine: a pilot double blind study. Cancer Drug Deliv 4:129-136, 1987.
58. Capizzi RL: Amifostine: the preclinical basis for broad spectrum selective cytoprotection of normal tissues from cytotoxic therapies. Semin Oncol 23(Suppl 8):2-17, 1996.
59. Yuhas JM: Active versus passive absorption kinetics as the basis for selective detection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 40:1519-1524, 1980.
60. Ohneshi ST, Ohneshi T, Glick JH, et al: In vitro study on the antioxidant activities of amifostine (WR-2721) [abstract]. Proc Am Assoc Cancer Res 33:419, 1992.
61. Dorr RT: Cytoprotective agents for anthracyclines. Semin Oncol 23(Suppl 8):23-34, 1996.
62. Creighton AM, Hellmann K, Whitecross S: Antitumor activity in a series of bisdiketopiperazines. Nature 222:384-385, 1969.
63. Herman E, Ferrans V, Myers C, et al: Comparison of the effectiveness of (+) 1-1,2-bis(3.5 dioxopiperazinyl-1-y1) propane (ICRF-187) and N-acetyl cysteine in preventing chronic doxorubin cardiotoxicity in beagles. Cancer Res 45:276-281, 1985.
64. Anonymous: Dexrazoxane for cardiac protection against doxorubicin. Med Lett 37:110-111, 1995.
65. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al: Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med. 319:745-752, 1988.
66. Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117-127, 1992.
67. Swain SM, Whaley FS, Gerber MC, et al: Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin containing therapy. J Clin Oncol 15:1333-1340, 1997.
68. Wexler LH, Andrich MP, Venzon D, et al: Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 14:362-372, 1996.
69. Holcenberg JS, Tutsch KD, Earhart RH, et al: Phase I study of ICRF-187 in pediatric cancer patients and comparison of its macokinetics in children and adults. Cancer Treat Rep 70:703-709, 1986.
70. Vats T, Kamen B, Krischer JP: Phase II trial of ICRF-187 in children with solid tumors and acute leukemia. Invest New Drugs 9:333-337, 1991.
71. Bu'Lock FA, Gabriel HM, Oakhill A, et al: Cardioprotection by ICRF-187 against high dose anthracycline toxicity in children with malignant disease. Br Heart J 70:185-188, 1993.
72. Xue Y, Lu D, Guo Y, et al: Specific chromosomal translocations and therapy-related leukemia induced by bimolane therapy for psoriasis. Leuk Res 16:1113-1123, 1992.
73. Posner LE, Kukart G, Goldberg J et al: Mitoxantrone: an overview of safety and toxicity. Invest New Drugs 3:123-132, 1985.
74. Cowan JD, Osborne CK, Neidhart JA, et al: A randomized trial of doxorubicin, mitoxantrone, and bisantrene in advanced breast cancer (a Southwest Oncology Group study). Invest New Drugs 3:147-152, 1985.
75. Henderson IG, Allegra JC, Woodcock T, et al: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 5610-5671, 1989.
76. Posner LE, Dukart G, Goldberg J, et al: Mitroxantrone: an overview of safety and toxicity. Invest New Drugs 3:123-132, 1985.
77. Allen A: The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 19:529-542, 1992.
78. Green MD, Alderton P, Sobol MM, et al: ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: clinical and pre-clinical studies. Cancer Treat Res 58:101-117, 1991.
79. Filippi JA, Imondi AR, Wolgemuth RL: Characterization of the cardioprotective effect of (S) (+)-4,4′-propylene-2,6-piperazinedione (ICRF-187) on anthracylcline cardiotoxicity. In: Organ-directed Toxicities of Anti-cancer Drugs, edited by MP Hacker, JS Lazo, TR Tritton, Boston, Martinus Nijhoff, 1988, p. 225.
80. Gottdiener JS, Appelbaum FR, Ferrans VJ, et al: Cardiotoxicity associated with high dose cyclophosphamide therapy. Arch Intern Med 141:758-763, 1981.
81. Cazin B, Gorin C, Laporte JP, et al: Cardiac complications after bone marrow transplantation: a report on a series of 63 consecutive transplantations. Cancer 57:2061-2069, 1986.
82. Goldberg MA, Antin JH, Guinan EC, et al: Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 68: 1114-1118, 1986.
83. Braverman AC, Antin JH, Plappert MT, et al: Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 9:1215-1223, 1991.
84. Voelcker G, Wagner T, Wientzek C, et al: Pharmacokinetics of "activated" cyclophosphamide and therapeutic efficacies. Cancer 54:1179-1186, 1984.
85. Bearman SI, Petersen FB, Schor RA, et al: Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. Bone Marrow Transplant 5:173, 1990.
86. Braverman AC, Antin JH, Plappert MT, et al: Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 9:1215, 1991.
87. Hertenstein B, Stefanic M, Schmeiser T, et al: Cardiac toxicity of bone marrow transplantation: preventive value of cardiologic evaluation before transplant. J Clin Oncol 12:998, 1994.
88. Weiss RB, Grillo-Lopez AJ, Marsoni S, et al: Amsacrine-associated cardiotoxicity: an analysis of 82 cases. J Clin Oncol 4:918-928, 1986,
89. Weiss RB, Moquin D, Adams JD, et al: Electrocardiogram abnormalities induced by amsacrine. Cancer Chemother Pharmacol 10:133-134, 1983.
90. Feldman EJ, Arlin ZA, Sullivan P, et al: Preventing amsacrine induced cardiac arrhythmias. J Clin Oncol 5:2041, 1987.
91. Rowinsky EK, McGuire WP, Guamieri T, et al: Cardiac disturbances during the administration of taxol. J Clin Oncol 9:1704-1712, 1991.
92. Arbuck SG, Strauss H, Rowisky E, et al: A reassessment of the cardiac toxicity of associated with taxol. Monogr Natl Cancer Inst 15:117-130, 1993.
93. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995.
94. Gehl J, Boesgaard M, Paaske T, et al: Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 7:687-693, 1996.
95. Millward LK, Cosson EJ, Stokes KH, et al: Cremophor EL changes the pharmacokinetics of doxorubicin [abstract 2221]. Proc Am Assoc Cancer Res 36:373, 1995.
96. Martin M, Lluch A, Ojeda B, et al: Paclitaxel plus doxorubicin in metastatic breast cancer: preliminary analysis of cardiotoxicity. Semin Oncol 24(Suppl 17):S17-26-S17-30, 1997.
97. Hortobagyi GN, Willey J, Rahman Z, et al: Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer. Semin Oncol 24(Suppl 17):S17-65-S17-68, 1997.
98. Dent R, McColl 1:5-Fluorouracil and angina. Lancet 1:347-348, 1975.
99. Lomeo AM, Avolio C, Iacobellis G, et al: 5-Fluorouracil cardiotoxicity. Eur J Gynaecol Oncol 3:237-241, 1990.
100. Keefe DL, Roistacher N, Pierri MK, et al: Clinical cardiotoxicity of 5-fluorouracil. J Clin Pharmacol 33:1060-1070, 1993.
101. Rezkalla S, Kloner RA, Ensley J, et al: Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective clinical study. J Clin Oncol 7:509-514, 1989.
102. Liss RH, Chadwick M: Correlation of 5-fluorouracil distribution in rodents with toxicity and chemotherapy in man. Cancer Chemother Rep 58:777-786, 1974.
103. Labinaca R, Beretta G, Clerici M, et al: Cardiac toxicity of 5-FU: a study of 1083 patients. Tumori 68:505-510, 1982.
104. Clavel M, Sorbette F, David M, et al: 5-Fluorouracil (5-FU) cardiotoxicity: 33 events out of 1145 consecutive patients. Proc Annu Meet Am Soc Clin Oncol 10:A346, 1991.
105. Robben NC, Pippas AW, Moore JO: The syndrome of 5-fluorouracil cardiotoxicity: an elusive cardiopathy. Cancer 71:493-509, 1993.
106. Rapoport AP, Rowe JM, Packman CH, et al: Cardiac arrest after autologous marrow transfusion. Bone Marrow Transplant 7: 401-403, 1991.
107. Kruit WH, Punt KJ, Goey SH, et al: Cardiotoxicity as a dose limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon: an unexpectedly frequent complication. Cancer 74:2850-2856, 1994.
108. Nora R, Abrams JS, Tait NS, et al: Myocardial toxic effects during IL-2 therapy. J Natl Cancer Inst 81:59-63, 1989.
109. Sonnenblick M, Rosin A: Cardiotoxicity of interferon: a review of 44 cases. Chest 99:557-561, 1991.
110. Stewart JR, Fajardo LF: Radiation-induced heart disease: an update. Prog Cardiovasc Dis 27:173-194, 1984.
111. Urba WJ, Longo DL: Hodgkin's disease. N Engl J Med 326: 678-687, 1992.
112. Polikar R, Burger AG, Scherre U, et al: The thyroid and the heart. Circulation 87:1435-1441, 1993.
113. Lipshultz, SE, Sallan SE: Editorial: cardiovascular abnormalities in long-term survivors of childhood malignancy. J Clin Oncol 11:1199-1203, 1993.
114. Hallahan DE, Haimovitz-Friedman A, Kufe D, et al: The role of cytokines in radiation oncology. In: Important Advances in Medical Oncology, edited by VT DeVita, S Hellman, S Rosenberg, Philadelphia-New York, Lippincott-Raven, 1993, pp. 71-80.
115. Green D, Gingell RL, Pearce J, et al: The effect of mediastinal irradiation on cardiac function of patients treated during childhood and adolescence for Hodgkin's disease. J Clin Oncol 5: 239, 1987.
116. Akaike A, Cogure R, Oyama K, et al: Damage to the heart from tumor irradiation in the thorax: an echocardiographic study. Radiology 25:430, 1985.
117. Fajardo LF, Stewart JR: Pathogenesis of radiation-induced myocardial fibrosis. Lab Invest 29:244-257, 1973.
118. Arsenian MA: Cardiovascular sequelae of therapeutic thoracic radiation. Prog Cardiovasc Dis 33:299-312, 1991.
119. Stewart JR, Fajardo LF: Radiation-induced heart disease. Radiol Clin North Am 3:511-531, 1971.
120. Loyer EM, Delpassand ES: Radiation-induced heart disease: imaging features. Semin Roentgenol 28:321-332, 1993.
121. Biran S: Corticosteroids in radiation-induced pericarditis. Chest 74:96-98, 1978.
122. Gomm SA, Stretton TB: Chronic pericardial effusion after mediastinal radiotherapy. Thorax 36:149-150, 1981.
123. Case records of the Massachusetts General Hospital (case 44-1981). N Engl J Med 305:1081-1087, 1981.
124. Green DM, Gingell RL, Pearce J, et al: The effect of mediastinal irradiation on cardiac function of patients treated during childhood and adolescence for Hodgkin's disease. J Clin Oncol 5: 239-245, 1987.
125. Applefeld MM, Cole JF, Pollock SH, et al: The late appearance of chronic pericardial disease in patients treated by radiotherapy for Hodgkin's's disease. Ann Intern Med 94:338-341, 1981.
126. Hancock EW: Subacute effusive-constrictive pericarditis. Circulation 43:183-192, 1971.
127. Ikaheimo MJ, Niemela KO, Linnaluoto MM, et al: Early cardiac changes related to radiation therapy. Am J Cardiol 56:943-946, 1985.
128. Burns RJ, Bar-Scholomo B, Druck MN, et al: Detection of radiation cardiomyopathy by gated radionuclide angiography. Am J Med 74:297-302, 1983.
129. Gottdiener JS, Katin MJ, Borer JS, et al: Late cardiac effects of therapeutic mediastinal irradiation. Assessment by echocardiography and radionuclide angiography. N Engl J Med 308:569-590, 1983.
130. Gustavsson A, Eskilsson J, Lanberg T, et al: Late cardiac effects after mantle radiotherapy in patients with Hodgkin's disease. Ann Oncol 1:355-363, 1990.
131. Pierga JY, Maunoury C, Valette H, et al: Follow-up thallium-201 scintigraphy after mantle field radiotherapy for Hodgkin's disease. Int J Radiat Oncol Biol Phys 25:871-876, 1993.
132. Masui T, Finck S, Higgins CB: Constrictive pericarditis and restrictive cardiomyopathy: evaluation with MR imaging. Radiology 182:369-373, 1992.
133. Schwartz RG, Zaret BL: The diagnosis and treatment of drug-induced myocardial disease. In: Cancer Treatment and the Heart, edited by FM Muggia, MD Green, JL Speyer, Boston, Johns Hopkins University Press, 1992, pp. 173-197.
134. Merrill J, Geco FA, Zimber H, et al: Adriamycin and radiation: synergistic cardiotoxicity. Ann Intern Med 82:122-123, 1975.
135. Kinsella TJ, Ahmann DL, Giuliani ER, et al: Adriamycin toxicity in stage IV breast cancer: possible enhancement with prior left chest radiation therapy. Int J Radiat Oncol Biol Phys 5:1979, 1979.
136. Brown TM, Fajardo LF, Stewart JR: Mural thrombosis of the heart induced by radiation. Arch Pathol 96:1-4, 1973.
137. Brosius FC, Waller BF, Roerts WC: Radiation heart disease: analysis of 16 young (aged 15-33 years) necropsy patients who received over 3500 rads to the heart. Am J Med 7:519, 1981.
138. Radwaner BA, Geringer R, Goldman AM, et al: Left main coronary artery stenosis following mediastinal irradiation. Am J Med 82:1017-1020, 1987.
139. Silverberg GD, Britt RH, Goffinet DR: Radiation-induced carotid artery disease. Cancer 41:130-137, 1978.
140. McEniery PT, Dorosti K, Schiavone WA, et al: Clinical and angiographic features of coronary artery disease after chest irradiation. Am J Cardiol 60:1020-1024, 1987.
141. Yahalom J, Hasin Y, Fulks Z: Acute myocardial infarction with normal coronary arteriogram after mantle field radiation therapy for Hodgkin's disease. Cancer 52:637-641, 1983.
142. Haimovitz-Friedman A, Vlodavsky I, Chaudhuri A, et al: Autocrine effects of fibroblast growth factor in radiation damage repair in endothelial cells. Cancer Res 51:2552-2558, 1991.
143. Fuks Z, Persaud RS, Alfieri A, et al: Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res 54:2582-2590, 1994.
144. Warda M, Khan A, Massumi A, et al: Radiation-induced valvular dysfunction. J Am Coll Cardiol 2:180-185, 1983.
145. Carlson RG, Mayfield WR, Normann S, et al: Radiation-associated valvular disease. Chest 99:538-545, 1991.
146. Slama MS, LeGuludec D, Sebag C, et al: Complete atrioventricular block following mediastinal irradiation: a report of six cases. PACE Pacing Clin Electrophysiol 14:1112-1118, 1991.
147. Strender LE, Lindahl J, Larsson LE: Incidence of heart disease and functional significance of change in the electrocardiogram 10 years after radiotherapy for breast cancer. Cancer 57:929-934, 1986.
148. Minow RA, Benjamin RS, Lee ET, et al: QRS voltage change with adriamycin administration. Cancer Treat Rep 62:931, 1978.
149. Schwartz CL, Hobbie WL, Truesdell A: Corrected QT interval prolongation in anthracycline treated survivors of childhood cancer. J Clin Oncol 11:1906, 1993.
150. Palmeri ST, Bonow RO, Meyers CE, et al: Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol 58:607-613, 1986.
151. Bloom K, Bini R, Williams C, et al: Echocardiography in adriamycin cardiotoxicity. Cancer 41:1265, 1978.
152. Borow K, Henderson I, Neuman A, et al: Assessment of left ventricular contractility in patients receiving doxorubicin. Ann Intern Med 99:750, 1983.
153. Sandor GGS, Puterman M, Rogers P, et al: Early prediction of anthracycline cardiomyopathy using standard M-mode and digitized echocardiography. Am J Pediatr Hematol Oncol 14:151, 1992.
154. Schwartz RG, McKenzie WB, Alexander S, et al: Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: a seven year experience using serial radionuclide angiocardiography. Am J Med 82:1109, 1987.
155. Lee BH, Goodenday LS, Muswick GJ, et al: Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol 9:184, 1987.
156. McKillop JH, Bristow MR, Goris ML, et al: Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 106:1048-1056, 1983.
157. Bristow MR, Mason JW, Billingham ME, et al: Dose effect and structure function relationships in doxorubicin cardiomyopathy. Am Heart J 102:709-718, 1981.
158. Steinherz LJ, Graham T, Hurwitz R, et al: Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children's Cancer Study Group. Pediatrics 89:942, 1992.
159. Lipshultz SE, Sanders SP, Goorin AM, et al: Monitoring for anthracycline cardiotoxicity. Pediatrics 93:433-437, 1994.
160. Dreyer Z, Guidry G, Mahoney D, et al: Tantalum-178 first pass radionuclide imaging (Ta-RNA) sensitive early detection of cardiac dysfunction (CD) in anthracycline (ANTH) treated pediatric patients. Proc Annu Meet Am Soc Clin Oncol 13: A1499, 1994.
161. Estroch M, Carrio I, Berna L, et al: Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J Nucl Med 31:1965, 1990.
162. Carrio I, Lopez-Pousa A, Estorch M, et al: Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies. J Nucl Med 34:1503, 1993.
163. Estorch M, Carrio I, Martinez-Duncker D, et al: Myocyte cell damage after administration of doxorubicin or mitoxantrone in antibody studies. S Clin Oncol 11:1264, 1993.
164. Wakasugi S, Fischman AJ, Babich JW, et al: Metaiodobenzyl-guanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy. J Nucl Med 34:1282, 1993.
165. Valdes Olmos RA, ten Bokkel Huinink WW, Greve JC, et al: 1-123 MIBG and serial radionuclide angiocardiography in doxorubicin-related cardiotoxicity. Clin Nucl Med 17:163, 1992.